{"id":"https://genegraph.clinicalgenome.org/r/2382bbff-0e1f-4079-9d76-2a403ae2c759v1.0","type":"EvidenceStrengthAssertion","dc:description":"The relationship between *D2HGDH* and *D2HGDH*-related primary mitochondrial disease was evaluated using the ClinGen Clinical Validity Framework as of October 2, 2023. The *D2HGDH* gene encodes D-2-hydroxyglutarate dehydrogenase, which is a mitochondrial enzyme that converts D-2-hydroxyglutarate into 2-ketoglutarate. \n\nThe *D2HGDH* gene was first reported in relation to *D2HGDH*-related primary mitochondrial disease in 2005 (PMID: 15609246). *D2HGDH* has been associated with a single disease entity to date, autosomal recessive D-2-hydroxyglutaric aciduria [OMIM#600721]. This is one disease entity according to the ClinGen Lumping and Splitting Framework, and has been renamed as *D2HGDH*-related primary mitochondrial disease.\n\nEvidence supporting this gene-disease relationship includes case-level data and experimental data. This curation included 10 unique variants (four missense, three splice, two frameshift, and one multi-exon deletion) identified in seven unrelated cases from five publications (PMIDs: 15609246, 16081310, 19169842, 20020533, 31431883). Clinical features in affected individuals are variable and range from early infantile-onset epileptic encephalopathy with hypotonia, delayed cerebral visual development, cardiomyopathy, dysmorphic facial features, and abnormalities on brain imaging to variable developmental delay and hypotonia. Biochemical lab abnormalities include elevated D-2-hydroxyglutaric acid (D-2-HG) in urine, plasma, and/or cerebrospinal fluid (CSF).\n\nThe mechanism of disease is loss of function. This gene-disease relationship is also supported by a biochemical function shared with other genes associated with primary mitochondrial disease, functional alteration studies in non-patient cells showing impaired D‐2‐HGDH enzyme activity, and a *C. elegans* model of D2HGDH deficiency that showed elevated 2-HG levels and mitochondrial defects compared to wild-type animals (PMIDs: 33340416, 30908763, 37043428). \n\nIn summary, there is definitive evidence to support the relationship between *D2HGDH* and *D2HGDH*-related primary mitochondrial disease. This relationship has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Gene Curation Expert Panel on October 2, 2023 (SOP Version 10).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/2382bbff-0e1f-4079-9d76-2a403ae2c759","GCISnapshot":"https://genegraph.clinicalgenome.org/r/90674a82-f43e-4435-88c8-121a57b8ab19","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/90674a82-f43e-4435-88c8-121a57b8ab19_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10027","date":"2025-10-06T21:49:01.165Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/90674a82-f43e-4435-88c8-121a57b8ab19_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10027","date":"2023-10-02T04:00:00.000Z","role":"Approver"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/90674a82-f43e-4435-88c8-121a57b8ab19_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5c9bc670-a0c1-482d-9708-df90402ff6c2_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f63519d6-78d4-4bcd-9b44-6fed7966ba18","type":"EvidenceLine","dc:description":"max 3 pt per case","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f63519d6-78d4-4bcd-9b44-6fed7966ba18_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"reduced D-2-HGDH enzyme activity in patient lymphoblasts \n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/f63519d6-78d4-4bcd-9b44-6fed7966ba18_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20020533","allele":{"id":"https://genegraph.clinicalgenome.org/r/f2198f6e-25df-4518-a803-c08c2e908111","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152783.5(D2HGDH):c.853+2T>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351407297"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/e1ef5c96-cfe2-4484-a1ee-6460457afd06","type":"EvidenceLine","dc:description":"max 3 pts per case","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e1ef5c96-cfe2-4484-a1ee-6460457afd06_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NMD expected\nFunctional: reduced D-2-HGDH enzyme activity in patient lymphoblasts \n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/e1ef5c96-cfe2-4484-a1ee-6460457afd06_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20020533","allele":{"id":"https://genegraph.clinicalgenome.org/r/d15fd0b6-0c3d-4ae2-806d-8ec4ea7bdaad","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152783.5(D2HGDH):c.642del (p.Arg215AspfsTer25)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA891843306"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/5c9bc670-a0c1-482d-9708-df90402ff6c2","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20020533","rdfs:label":"Kranendijk Patient 6","allele":[{"id":"https://genegraph.clinicalgenome.org/r/d15fd0b6-0c3d-4ae2-806d-8ec4ea7bdaad"},{"id":"https://genegraph.clinicalgenome.org/r/f2198f6e-25df-4518-a803-c08c2e908111"}],"detectionMethod":"single-gene testing for D2HGDH","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Individual clinical details not provided\nAll patients included had increased levels of D-2-HG in urine, plasma, and/or cerebrospinal fluid (CSF) \n","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/e1ef5c96-cfe2-4484-a1ee-6460457afd06_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/f63519d6-78d4-4bcd-9b44-6fed7966ba18_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/5a39dfca-e57d-4db4-a872-f837b52e1a3b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a48e6103-8e69-4e63-948c-c62ce8b769c9","type":"EvidenceLine","dc:description":"Deletion of exons 3-10 of D2HGDH, predicted to undergo NMD\n","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a48e6103-8e69-4e63-948c-c62ce8b769c9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31431883","allele":{"id":"https://genegraph.clinicalgenome.org/r/5807af9f-142f-4fe1-95ad-0962c89103f7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000002.12:g.(?_241741010)_(241767989_?)del","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/539292"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/5a39dfca-e57d-4db4-a872-f837b52e1a3b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31431883","rdfs:label":"Phillips case report","ageType":"AgeAtReport","ageUnit":"Years","ageValue":5,"allele":{"id":"https://genegraph.clinicalgenome.org/r/5807af9f-142f-4fe1-95ad-0962c89103f7"},"detectionMethod":"Single-gene testing for 4 genes associated with L- and D-HGA\n","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Clinical phenotype – speech delay, dev/del, mild hypotonia\n\nLaboratory findings: Elevated levels of D-2-HG in urine: 1348 mmol/mol Cr and 1497 mmol/mol Cr (normal <20 mmol/mol Cr)\n","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/a48e6103-8e69-4e63-948c-c62ce8b769c9_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/30913279-a8e7-4733-a8c6-e1529381880a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2ea60f4b-42a9-4394-a56f-f1ff25177cc5","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2ea60f4b-42a9-4394-a56f-f1ff25177cc5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RT-PCR w/ cyclohexamine showed the variant creates an alternative splice acceptor 19 nt upstream of the wt splice site, resulting in a frameshift that causes a premature stop codon (p.Cys100fsTer9). RT-PCR w/o cyclohexamine confirmed absence of this allele and suggests NMD occurs.\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/2ea60f4b-42a9-4394-a56f-f1ff25177cc5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15609246","allele":{"id":"https://genegraph.clinicalgenome.org/r/eed36940-33de-4bf4-9104-28faa0e975f8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152783.5(D2HGDH):c.293-23A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA540589431"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/92f0bc0d-d9f1-442b-818b-99ec2908dff3","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/92f0bc0d-d9f1-442b-818b-99ec2908dff3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"reduced D-2-HGDH enzyme activity in HEK293 cells (~0% residual activity; PMID 30908763) ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/92f0bc0d-d9f1-442b-818b-99ec2908dff3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15609246","allele":{"id":"https://genegraph.clinicalgenome.org/r/b5172770-575e-4519-a3a5-194003467e5f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152783.5(D2HGDH):c.440T>G (p.Ile147Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115237"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/30913279-a8e7-4733-a8c6-e1529381880a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15609246","rdfs:label":"Struys Patient 2","allele":[{"id":"https://genegraph.clinicalgenome.org/r/b5172770-575e-4519-a3a5-194003467e5f"},{"id":"https://genegraph.clinicalgenome.org/r/eed36940-33de-4bf4-9104-28faa0e975f8"}],"detectionMethod":"Single-gene testing of D2HGDH","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Developmental delay, seizures, infantile spasms with hypsarrhythmia, hypotonia, and cortical blindness\nLaboratory findings: Quantitative measurements of D-2-HG showed urine levels at 1747 mM/M creatinine (normal <18mM/M creatinine), plasma levels at 73 mM/l (normal, <1mM/l), and cerebrospinal fluid levels at 25 mM/l (normal, <0.4mM/l).\n","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/2ea60f4b-42a9-4394-a56f-f1ff25177cc5_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/92f0bc0d-d9f1-442b-818b-99ec2908dff3_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/516418fe-10ce-4762-a91b-658c98752354_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d2aa1a56-8385-44a3-9062-c4d7495a8590","type":"EvidenceLine","dc:description":"max 3 pts per case","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d2aa1a56-8385-44a3-9062-c4d7495a8590_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"reduced D-2-HGDH enzyme activity in patient fibroblasts \n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/d2aa1a56-8385-44a3-9062-c4d7495a8590_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20020533","allele":{"id":"https://genegraph.clinicalgenome.org/r/f39c1f6a-2317-46b1-97d0-fefc4532ca44","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152783.5(D2HGDH):c.685-2A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2221747"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/516418fe-10ce-4762-a91b-658c98752354","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20020533","rdfs:label":"Kranendijk Patient 2","allele":{"id":"https://genegraph.clinicalgenome.org/r/f39c1f6a-2317-46b1-97d0-fefc4532ca44"},"detectionMethod":"Single-gene testing of D2HGDH","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Individual clinical details provided in PMID: 16037974\nTwo siblings had a mild form for D-2-HGA\nBoth patients had increased levels of D-2-HG in urine, plasma, and/or cerebrospinal fluid (CSF) \n","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/d2aa1a56-8385-44a3-9062-c4d7495a8590_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/244bb0d7-ea82-4bd0-a5e5-f754ede48a3b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aa30bc2d-063d-4b69-8b42-47bd6665ef2d","type":"EvidenceLine","dc:description":"NMD expected","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aa30bc2d-063d-4b69-8b42-47bd6665ef2d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16081310","allele":{"id":"https://genegraph.clinicalgenome.org/r/8439671b-be51-422e-863d-2f4a2956e55e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152783.5(D2HGDH):c.325_326dup (p.Glu110ArgfsTer18)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2221595"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/b1aef134-b433-44e1-b603-45b14161ed45","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b1aef134-b433-44e1-b603-45b14161ed45_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"reduced D-2-HGDH enzyme activity in HEK293 cells (~15% residual activity; PMID 30908763)\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/b1aef134-b433-44e1-b603-45b14161ed45_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16081310","allele":{"id":"https://genegraph.clinicalgenome.org/r/134b372d-a7d5-4d80-9a29-25ae5adc3068","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152783.5(D2HGDH):c.1123G>T (p.Asp375Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115239"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/244bb0d7-ea82-4bd0-a5e5-f754ede48a3b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16081310","rdfs:label":"Misra twin probands","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/8439671b-be51-422e-863d-2f4a2956e55e"},{"id":"https://genegraph.clinicalgenome.org/r/134b372d-a7d5-4d80-9a29-25ae5adc3068"}],"detectionMethod":"Single-gene sequencing of D2HGDH","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Twin 1 – dev/del and hypotonia that progressed to severe epileptic encephalopathy, dysmorphic facial features, abnormal brain MRI (ventriculomegaly, cortical atrophy, and periventricular leukomalacia)\nTwin 2 – minor facial dysmorphism and macrocephaly, no other clinical phenotypes\nLaboratory findings: Elevated urinary 2-HG in both twins (230 mmol/mol creatinine in Twin 1 (severely affected) and 430 mmol/mol creatinine in Twin 2 (mildly/unaffected). Subsequent analysis by isotope dilution showed the elevation was the D-2-HG form.\n\n","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/aa30bc2d-063d-4b69-8b42-47bd6665ef2d_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/b1aef134-b433-44e1-b603-45b14161ed45_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/51719481-4620-4117-9e9f-a3252a472b25_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8447ff82-5db0-465a-a27e-bd57600263ad","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8447ff82-5db0-465a-a27e-bd57600263ad_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"reduced D-2-HGDH enzyme activity in HEK293 cells (~25% residual activity; PMID 30908763)\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/8447ff82-5db0-465a-a27e-bd57600263ad_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15609246","allele":{"id":"https://genegraph.clinicalgenome.org/r/e50542e7-706b-4054-939a-5108e74aced4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152783.5(D2HGDH):c.1331T>C (p.Val444Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115236"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/51719481-4620-4117-9e9f-a3252a472b25","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15609246","rdfs:label":"Struys Patient 1","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/e50542e7-706b-4054-939a-5108e74aced4"},"detectionMethod":"Single gene sequencing of the D2HGDH gene","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Developmental delay, mild facial dysmorphism, episodes of vomiting, seizures\nLaboratory findings: Quantitative measurements of D-2-HG showed urine levels at 502 mM/M creatinine (normal <18mM/M creatinine), plasma levels at 26 mM/l (normal, <1mM/l), and cerebrospinal fluid levels at 6 mM/l (normal, <0.4mM/l).\n","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/8447ff82-5db0-465a-a27e-bd57600263ad_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/7d01b670-6873-44eb-bcc2-53bd08b5fca3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3b294cb4-e57e-497c-83fe-653b1c9ebfde","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3b294cb4-e57e-497c-83fe-653b1c9ebfde_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"reduced D-2-HGDH enzyme activity in HEK293 cells (~0% residual activity; PMID 30908763) ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/3b294cb4-e57e-497c-83fe-653b1c9ebfde_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19169842","allele":{"id":"https://genegraph.clinicalgenome.org/r/85393865-a24a-4344-bd16-890efbdd2a33","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152783.5(D2HGDH):c.458T>C (p.Met153Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351406374"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/7d01b670-6873-44eb-bcc2-53bd08b5fca3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19169842","rdfs:label":"Haliloglu case report","ageType":"AgeAtReport","ageUnit":"Years","ageValue":16,"allele":{"id":"https://genegraph.clinicalgenome.org/r/85393865-a24a-4344-bd16-890efbdd2a33"},"detectionMethod":"Single-gene testing of D2HGDH","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Global dev/del, mild ID, dysarthria, dystonia, ataxic gait, cardiomyopathy, abnormalities on brain MRI (Fig. 1)\n\nLaboratory findings: Elevated urinary 2-HG 5070 mmol/mol creatinine (most in D-form by enantiomer study)\n","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/3b294cb4-e57e-497c-83fe-653b1c9ebfde_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/90674a82-f43e-4435-88c8-121a57b8ab19_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/90674a82-f43e-4435-88c8-121a57b8ab19_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6adb5bac-59d6-4b55-afb6-69c2c201c176","type":"EvidenceLine","dc:description":"Reduced points due to lower organism, but scored based on similar biochemical defect as in humans and some abnormal mitochondrial morphology.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8d24c9d7-b5a2-47a0-b3b2-44eb6248904f","type":"Finding","dc:description":"Used a C.elegans model of D2HGDH. The C.elegans dhgd-1 sequence is 46% identical to human D2HGDH and contains the same conserved functional domains. A dhgd-1 mutant was generated that lacks the 5’ end of the gene, which is predicted to result in loss-of-function (referred to as Δdhgd-1 mutants). Δdhgd-1 mutants showed elevated 2-HG compared to wild-type animals, and enantiomer analysis indicated this is D-2-HG. Δdhgd-1 mutants had embryonic lethality (~67% failed to hatch) and showed mitochondrial defects (mitochondrial network is more fragmented and individual mitochondria more rounded).\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37043428","rdfs:label":"C.elegans model system","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/90674a82-f43e-4435-88c8-121a57b8ab19_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6e04af3a-9c6f-408d-8dee-6a8c55c370d6","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9a15faac-1842-48b5-85da-c96f1cdd1e14","type":"FunctionalAlteration","dc:description":"Site‐directed mutagenesis was used to introduce 31 missense variants in the pCMV5‐D2HGDH expression vector. The wild type and missense variants were overexpressed in HEK293 cells. D‐2‐HGDH enzyme activity was evaluated based on the conversion of D‐2‐HG to 2‐ketoglutarate, which was subsequently converted into L‐glutamate and the latter quantified by LC‐MS/MS.\n18 missense variants significantly impaired D-2-HGDH activity (<6% of wild type activity) and 13 variants had between 17-94% enzyme activity.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30908763","rdfs:label":"Functional alteration non-patient cells"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/90674a82-f43e-4435-88c8-121a57b8ab19_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/693be318-9f7d-4c24-ac19-3a2e6acaa1f5","type":"EvidenceLine","dc:description":"applied per GCEP guidance document","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/09e81196-0fe0-4bd8-9887-a6dd8768ab2f","type":"Finding","dc:description":"D2HGDH is included in disorders of mitochondrial metabolite repair, which also includes the following genes associated with PMD: L2HGDH and ACSF3. IDH2 and SLC25A1 are also associated with D-2-hydroxyglutaric aciduria and combined D-2- and L-2-hydroxyglutaric aciduria, respectively, and similar clinical phenotypes.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33340416","rdfs:label":"Biochemical function 1","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2}],"evidenceStrength":"Definitive","sequence":11939,"specifiedBy":"GeneValidityCriteria10","strengthScore":14,"subject":{"id":"https://genegraph.clinicalgenome.org/r/IXqwBkhJFCk","type":"GeneValidityProposition","disease":"obo:MONDO_0044970","gene":"hgnc:28358","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_90674a82-f43e-4435-88c8-121a57b8ab19-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}